Individual Bioequivalence: Strengths and Weaknesses of the Current Approach: View from the Generic Pharmaceutical Association by MDS Pharma Services FDA.

Slides:

Advertisements

Similar presentations

Applying Multilevel Models in Evaluation of Bioequivalence in Drug Trials Min Yang Prof of Medical Statistics Nottingham Clinical Trials Unit School of.

Advertisements

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

Presentation of BE data in a product dossier Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.

What is the experimental unit in premix bioequivalence ? June 2010 Didier Concordet

Kamal K. Midha C.M., Ph.D, D.Sc College of Pharmacy and Nutrition,

Reading the Dental Literature

Sample size optimization in BA and BE trials using a Bayesian decision theoretic framework Paul Meyvisch – An Vandebosch BAYES London 13 June 2014.

Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Statistical Considerations for Bioequivalence.

Bioequivalence of Highly Variable (HV) Drugs: Clinical Implications Why HV Drugs are Safer Leslie Z. Benet, Ph.D. Professor of Biopharmaceutical Sciences.

Notes Grading Scale now posted on website.

Stefan Franzén Introduction to clinical trials.

Introduction into the workshop Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.

VINOD P. SHAH, PH.D. SENIOR RESEARCH SCIENTIST OFFICE OF PHARMACEUTICAL SCIENCE CENTER FOR DRUG EVALUATION AND RESEARCH FOOD AND DRUG ADMINISTRATION Pharmacy.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.

WHO Prequalification Program Workshop, Kiev, Ukraine, June 25-27,2007.

Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.

FDA Nasal BA/BE Guidance Overview

Qian H. Li, Lawrence Yu, Donald Schuirmann, Stella Machado, Yi Tsong

Bioequivalence Studies Dr Sanet Aspinall, PhD Managing Director AddClin Research Pretoria 20 March 2009.

Organizational Gaps in Reaching the “Desired State” Helen Winkle.

1 Experimental Study Designs Dr. Birgit Greiner Dep. of Epidemiology and Public Health.

Stefan Franzén Introduction to clinical trials.

Results from Replicate Design Studies in ANDAs Rabi Patnaik, Ph.D. Division of Bioequivalence Office of Generic Drugs Office of Pharmaceutical Science,

SFDA-2007 الهيئة العامة للغذاء والدواء Bioequivalence Studies of Generic Pharmaceutical Products Workshop-Day II Introduction and workshop Objectives By:

1 Bioequivalence of Highly Variable Drugs: Regulatory Perspectives Sam H. Haidar, R.Ph., Ph.D. Pharmacometrics Office of Generic Drugs.

Biomedical Research Objective 2 Biomedical Research Methods.

Week 6- Bioavailability and Bioequivalence

Regulatory requirements Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.

ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,

Highly Variable Drugs – Bioequivalence Issues: FDA Proposal Under Consideration Barbara M. Davit, J.D., Ph.D. Deputy Director, Division of Bioequivalence.

Topics Appropriate to Experiments Projects with limited and well-defined concepts. Projects that are exploratory rather than descriptive. Studies of small.

Critical Appraisal of the Scientific Literature

Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.

1 ORALLY INHALED AND NASAL DRUG PRODUCTS FOR LOCAL ACTION Current FDA BA/BE Background and Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA OINDP Subcommittee.

Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.

Statistical considerations Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.

1 DepoCyt®: Enrollment Completed Oncology Drugs Advisory Committee November 8, 2005 Gordon L. Schooley, Ph.D. Chief Scientific Officer SkyePharma Inc.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

1 Abu Alam Ph.D. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 23, 2008.

Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview

August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.

1 EVALUATION OF BIOEQUIVALENCE FOR HIGHLY-VARIABLE DRUGS AND DRUG PRODUCTS Laszlo Endrenyi University of Toronto Laszlo Tothfalusi Semmelweis University.

Bioequivalence Dr Mohammad Issa Saleh.

Guidance Update: Average, Population, and Individual Approaches to Establishing Bioequivalence Mei-Ling Chen, Ph.D. Associate Director Office of Pharmaceutical.

Dermatopharmacokinetics (DPK)

Pre-qualification Program: Priority Medicines Interchangeability of Multi Source Drug Products SALOMON STAVCHANSKY, PH.D. ALCON CENTENNIAL PROFESSOR OF.

Using Product Development Information to Address the Bioequivalence Challenges of Highly-variable Drugs Lawrence X. Yu, Ph. D. Director for Science Office.

Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.

Examples of deficiencies in submitted data Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

BE Issues of HVD & HVDP Kamal K. Midha, Maureen Rawson Gordon McKay & John W. Hubbard PharmaLytics Inc. A Non-Profit Institute of the University of Saskatchewan.

Why Highly Variable Drugs are Safer Leslie Z. Benet, Ph.D. Professor of Biopharmaceutical Sciences University of California San Francisco FDA Advisory.

Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.

Individual Bioequivalence: Have the Opinions of the Scientific Community Changed? Leslie Z. Benet, Ph.D. University of California San Francisco.

Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.

Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Statistical Considerations.

Pharmacogenetics (PGx) of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism: Background Clinical Pharmacology Subcommittee of ACPS November.

Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.

Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.

Evaluation of a Scaling Approach for Highly Variable Drugs Sam H. Haidar, Ph.D., R.Ph. Office of Generic Drugs Advisory Committee for Pharmaceutical Sciences.

4.1 Statistics Notes Should We Experiment or Should We Merely Observe?

1. Objectives Novartis is developing a new triple fixed-dose combination product. As part of the clinical pharmacology program, pharmacokinetic (PK) drug-drug.

SOME ISSUES ON THE DETERMINATION OF BIOEQUIVALENCE FOR HIGHLY VARIABLE DRUGS Laszlo Endrenyi University of Toronto Laszlo Tothfalusi Semmelweis University.

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:

Analgesic Drug Development for Chronic Pain A Brief to the FDA Arthritis Advisory Committee July 29, 2002 Najib Babul, PharmD.

Chapter 8 Experiments.

Why experimental design are important

How to evaluate a piece of research

Bioequivalence trials: design, evaluation, regulatory requirements

Objective 2 Biomedical Research Methods

Presentation transcript:

Individual Bioequivalence: Strengths and Weaknesses of the Current Approach: View from the Generic Pharmaceutical Association by MDS Pharma Services FDA Advisory Committee Pharmaceutical Sciences November 29, 2001 Mario Tanguay, BPharm, PhD Associate Director, Pharmacokinetics

Individual Bioequivalence Collaborators GPhA Science and CRO/Biopharmaceutics Committees MDS Pharma Services –Murray P. Ducharme, PharmD, FCCP, FCP –Marika Pasternyk DiMarco, MSc, PhD –Diane Potvin, MSc

Individual Bioequivalence Advantages of IBE Enables one to capture the advantages of giving the same formulation twice –Replicate design has no real benefit when ABE is used IBE may be ethically advantageous –Smaller sample size needed for highly variable drugs due to the scaling component

Individual Bioequivalence Disadvantages of IBE How robust is the assessment of switchability with current IBE approach? –BE studies are primarily designed to prove bioequivalence based on Cmax and AUCs calculations –Current BE studies are not designed to allow proper determination of a Subject * Form interaction  Reason(s) for Subject * Form interaction cannot be identified properly

Individual Bioequivalence Disadvantages of IBE Enrollment of a heterogeneous population may not be helpful –BE Studies are not properly designed to evaluate Gender differences in PK Age differences in PK Race differences in PK etc...

Individual Bioequivalence Disadvantages of IBE In clinical research, conclusions based on posteriori statistical subgroup evaluations have many times been proven to be wrong when verified in properly designed prospective studies. These lessons should apply to switchability measurement in BE studies

Individual Bioequivalence Conclusion The BE of 2 formulations of a highly variable drug will be better assessed by giving a formulation more than once to the same subject However, it is not appropriate to assume that switchability is robustly assessed with IBE –Posteriori subgroup calculations (study not designed for this) –Contrary to the lessons we have learned over the years in Clinical Pharmacology